Article
Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.
Antiviral therapy - 1 Jan 2014
Taylor Ninon, Haschke-Becher Elisabeth, Greil Richard, Strasser Michael, Oberkofler Hannes
Abstract excerpt
BACKGROUND: With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS: Two different real-time PCR platforms, the COBAS Ampliprep/COBAS TaqMan v2.0 (CAP-CTM v2.0) and the Abbott RealTime (ART) HCV assay are most...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.